This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Braxia Scientific (formerly Champignon Brands) is leading the way in providing people who suffer from mental illness access to breakthrough treatments through our growing global network of multidisciplinary clinics while setting the standard of care. Braxia Scientific also aims to develop innovative ketamine and psychedelic drug formulations to provide high impact solutions for the future.
Stock Performance
Braxia Scientific News 32 articles
- Braxia Scientific Announces Change in Directors and CEO
- Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
- Braxia Announces Annual General and Special Meeting
- Braxia Scientific Announces Cease Trade Order
- Braxia Scientific Provides Update on Application for Management Cease Trade Order
- Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
- Braxia Scientific Corp. Delays Financial Report Amid Management Changes
- Braxia Scientific Corp Shows Resilience Amid Financial Challenges
- Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
- Braxia Scientific Financial Report Analysis
- Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
- Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US
- Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America
- Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
- KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers
- Braxia Scientific Announces Board Appointment
- Braxia Scientific Announces Court Approval of Class Action Settlement in Canada
- Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home
- Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
- Roger McIntyre, CEO of Braxia Scientific, Sits in the Investor Hotseat on August 18th
- Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.
- Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
- Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth
- Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders
- Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
- Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami
- Braxia Scientific Reports Encouraging Results of Ketamine Study
- Braxia Scientific Comments on US Class Action
- Braxia Scientific Announces Participation at PSYCH Investor Summit on July 7, 2021
- American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre
- Braxia Scientific Announces Symbol Change on OTC Markets to “BRAXF”
- Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Psychedelic Research